Compare MYGN & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | MOBI |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.1M | 383.0M |
| IPO Year | 1996 | 2026 |
| Metric | MYGN | MOBI |
|---|---|---|
| Price | $4.08 | $9.32 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $7.64 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 191.7K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $6.86 | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $2.74 | $9.49 |
| 52 Week High | $8.59 | $15.19 |
| Indicator | MYGN | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 38.36 |
| Support Level | $2.89 | N/A |
| Resistance Level | $5.42 | $12.37 |
| Average True Range (ATR) | 0.23 | 0.69 |
| MACD | 0.12 | -0.10 |
| Stochastic Oscillator | 86.49 | 5.95 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.